Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Danson

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Expert Opinion on Pharmacotherapy|June 17, 2005
Perspectives on novel therapies for bronchial carcinomaFiona Blackhall, Pavlos I Papakotoulas, Sarah Danson, et al.
The Lancet. Oncology|October 7, 2004
Assessment of therapeutic response in patients with metastatic bone diseaseAndrew Clamp, Sarah Danson, Huy Nguyen, et al.
International Journal of Oncology|September 7, 2011
Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cellsRuth Thompson, Mark Meuth, Penella Woll, et al.
Lancet (London, England)|August 28, 2015
Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasmsSally Thomas, Katherine Fisher, John Snowden, et al.
Biomolecules|May 4, 2026
Exercise Boosts the Immune System and Enhances Immunotherapy Responses in Pancreatic Cancer and MesotheliomaBrindley Hapuarachi, Sarah Danson, Jonathan Wadsley, et al.
Immunotherapy Advances|January 12, 2026
The UK vaccine innovation pathwaySarah Danson, Robert P Jones, Kristina Duggleby, et al.
Journal of Comorbidity|November 2, 2017
The acute oncologist's role in managing patients with cancer and other comorbiditiesKate Shankland, Peter Kirkbride, Anne-Marie Bourke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trialMiranda Payne, Paul Ellis, David Dunlop, et al.
British Journal of Health Psychology|June 12, 2025
Assessing moral injury in health care workers living in secular societies: Introducing the Health care-Moral Injury Scale (HMIS)Kathryn Fradley, Fuschia Sirois, Richard Bentall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancerKenneth J O'Byrne, Sarah Danson, David Dunlop, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Expert Opinion on Pharmacotherapy|June 17, 2005
Perspectives on novel therapies for bronchial carcinomaFiona Blackhall, Pavlos I Papakotoulas, Sarah Danson, et al.
The Lancet. Oncology|October 7, 2004
Assessment of therapeutic response in patients with metastatic bone diseaseAndrew Clamp, Sarah Danson, Huy Nguyen, et al.
International Journal of Oncology|September 7, 2011
Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cellsRuth Thompson, Mark Meuth, Penella Woll, et al.
Lancet (London, England)|August 28, 2015
Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasmsSally Thomas, Katherine Fisher, John Snowden, et al.
Biomolecules|May 4, 2026
Exercise Boosts the Immune System and Enhances Immunotherapy Responses in Pancreatic Cancer and MesotheliomaBrindley Hapuarachi, Sarah Danson, Jonathan Wadsley, et al.
Immunotherapy Advances|January 12, 2026
The UK vaccine innovation pathwaySarah Danson, Robert P Jones, Kristina Duggleby, et al.
Journal of Comorbidity|November 2, 2017
The acute oncologist's role in managing patients with cancer and other comorbiditiesKate Shankland, Peter Kirkbride, Anne-Marie Bourke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trialMiranda Payne, Paul Ellis, David Dunlop, et al.
British Journal of Health Psychology|June 12, 2025
Assessing moral injury in health care workers living in secular societies: Introducing the Health care-Moral Injury Scale (HMIS)Kathryn Fradley, Fuschia Sirois, Richard Bentall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancerKenneth J O'Byrne, Sarah Danson, David Dunlop, et al.
Pageof 7